Platelets Are at the Nexus of Vascular Diseases

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2019 Oct 2

PMID 31572732

Citations 39

Authors

Heloise Lebas

Katia Yahiaoui

Raphael Martos

Yacine Boulaftali

Affiliations

Soon will be listed here.

Abstract

Platelets are important actors of cardiovascular diseases (CVD). Current antiplatelet drugs that inhibit platelet aggregation have been shown to be effective in CVD treatment. However, the management of bleeding complications is still an issue in vascular diseases. While platelets can act individually, they interact with vascular cells and leukocytes at sites of vascular injury and inflammation. The main goal remains to better understand platelet mechanisms in thrombo-inflammatory diseases and provide new lines of safe treatments. Beyond their role in hemostasis and thrombosis, recent studies have reported the role of several aspects of platelet functions in CVD progression. In this review, we will provide a comprehensive overview of platelet mechanisms involved in several vascular diseases.

Citing Articles

Nationwide Analysis (2016-2020) of the Burden of Thrombocytopenia on Patients Admitted Due to Myocardial Infarction, Heart Failure or Atrial Fibrillation.

Siochi C, Lerman B, Nwachukwu C, Cervantes W, Durodola B, Villarrubia Varela L Cureus. 2025; 17(2):e78452.

PMID: 40051938 PMC: 11882357. DOI: 10.7759/cureus.78452.

Demographic diversity in platelet function and response to antiplatelet therapy.

Jain K, Tyagi T, Gu S, Faustino E, Hwa J Trends Pharmacol Sci. 2024; 46(1):78-93.

PMID: 39672782 PMC: 11710996. DOI: 10.1016/j.tips.2024.11.005.

A Co-Culture System for Studying Cellular Interactions in Vascular Disease.

Padmanaban A, Ganesan K, Ramkumar K Bioengineering (Basel). 2024; 11(11).

PMID: 39593750 PMC: 11591305. DOI: 10.3390/bioengineering11111090.

Human Disabled-2 regulates thromboxane A signaling for efficient hemostasis in thrombocytopenia.

Tsai H, Chang Y, Hsieh Y, Wang J, Wu C, Ho M Nat Commun. 2024; 15(1):9816.

PMID: 39537612 PMC: 11561248. DOI: 10.1038/s41467-024-54093-5.

Controlled human exposures: a review and comparison of the health effects of diesel exhaust and wood smoke.

Long E, Rider C, Carlsten C Part Fibre Toxicol. 2024; 21(1):44.

PMID: 39444041 PMC: 11515699. DOI: 10.1186/s12989-024-00603-8.

References

Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C . Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med. 2013; 369(1):11-9. DOI: 10.1056/NEJMoa1215340. View

Ganbaatar B, Fukuda D, Salim H, Nishimoto S, Tanaka K, Higashikuni Y . Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice. Atherosclerosis. 2018; 275:124-132. DOI: 10.1016/j.atherosclerosis.2018.05.053. View

Stefanini L, Bergmeier W . CalDAG-GEFI and platelet activation. Platelets. 2010; 21(4):239-43. PMC: 4119791. DOI: 10.3109/09537101003639931. View

Striggow F, Riek-Burchardt M, Kiesel A, Schmidt W, Henrich-Noack P, Breder J . Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. Eur J Neurosci. 2001; 14(4):595-608. DOI: 10.1046/j.0953-816x.2001.01676.x. View

Tekelioglu Y, Uzun H . Circulating platelet-leukocyte aggregates in patients with inflammatory bowel disease. J Chin Med Assoc. 2013; 76(4):182-5. DOI: 10.1016/j.jcma.2012.12.015. View

Kraus S, Naumov I, Shapira S, Kazanov D, Aroch I, Afek A . Aspirin but not meloxicam attenuates early atherosclerosis in apolipoprotein E knockout mice. Isr Med Assoc J. 2014; 16(4):233-8. View

Vivekananthan D, Bhatt D, Chew D, Zidar F, Chan A, Moliterno D . Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004; 94(3):358-60. DOI: 10.1016/j.amjcard.2004.04.035. View

Takaya N, Katoh Y, Iwabuchi K, Hayashi I, Konishi H, Itoh S . Platelets activated by collagen through the immunoreceptor tyrosine-based activation motif in the Fc receptor gamma-chain play a pivotal role in the development of myocardial ischemia-reperfusion injury. J Mol Cell Cardiol. 2005; 39(6):856-64. DOI: 10.1016/j.yjmcc.2005.07.006. View

Allaire E, Muscatelli-Groux B, Guinault A, Pages C, Goussard A, Mandet C . Vascular smooth muscle cell endovascular therapy stabilizes already developed aneurysms in a model of aortic injury elicited by inflammation and proteolysis. Ann Surg. 2004; 239(3):417-27. PMC: 1356242. DOI: 10.1097/01.sla.0000114131.79899.82. View

10.

McNeil J, Wolfe R, Woods R, Tonkin A, Donnan G, Nelson M . Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. N Engl J Med. 2018; 379(16):1509-1518. PMC: 6289056. DOI: 10.1056/NEJMoa1805819. View

11.

Mao Y, Zhang M, Tuma R, Kunapuli S . Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J Cereb Blood Flow Metab. 2010; 30(5):1044-52. PMC: 2949190. DOI: 10.1038/jcbfm.2009.283. View

12.

Stegner D, Nieswandt B . Platelet receptor signaling in thrombus formation. J Mol Med (Berl). 2010; 89(2):109-21. DOI: 10.1007/s00109-010-0691-5. View

13.

Romo G, Dong J, Schade A, Gardiner E, Kansas G, Li C . The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin. J Exp Med. 1999; 190(6):803-14. PMC: 2195629. DOI: 10.1084/jem.190.6.803. View

14.

Preusch M, Rusnak J, Staudacher K, Mogler C, Uhlmann L, Sievers P . Ticagrelor promotes atherosclerotic plaque stability in a mouse model of advanced atherosclerosis. Drug Des Devel Ther. 2016; 10:2691-9. PMC: 5008449. DOI: 10.2147/DDDT.S105718. View

15.

Dotsenko O, Chaturvedi N, Thom S, Wright A, Mayet J, Shore A . Platelet and leukocyte activation, atherosclerosis and inflammation in European and South Asian men. J Thromb Haemost. 2007; 5(10):2036-42. PMC: 2650817. DOI: 10.1111/j.1538-7836.2007.02711.x. View

16.

Reed G, Rossi J, Cannon C . Acute myocardial infarction. Lancet. 2016; 389(10065):197-210. DOI: 10.1016/S0140-6736(16)30677-8. View

17.

Nachman R, Rafii S . Platelets, petechiae, and preservation of the vascular wall. N Engl J Med. 2008; 359(12):1261-70. PMC: 2935201. DOI: 10.1056/NEJMra0800887. View

18.

Frostegard J . Immunity, atherosclerosis and cardiovascular disease. BMC Med. 2013; 11:117. PMC: 3658954. DOI: 10.1186/1741-7015-11-117. View

19.

Rubiera M, Alvarez-Sabin J, Ribo M, Montaner J, Santamarina E, Arenillas J . Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke. 2005; 36(7):1452-6. DOI: 10.1161/01.STR.0000170711.43405.81. View

20.

Leonardi S, Tricoci P, White H, Armstrong P, Huang Z, Wallentin L . Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial. Eur Heart J. 2013; 34(23):1723-31. DOI: 10.1093/eurheartj/eht104. View